BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008;41:597-604. [PMID: 18176611 DOI: 10.1038/sj.bmt.1705968] [Cited by in Crossref: 90] [Cited by in F6Publishing: 93] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Fay CJ, Awh KC, LeBoeuf NR, Larocca CA. Harnessing the immune system in the treatment of cutaneous T cell lymphomas. Front Oncol 2022;12:1071171. [PMID: 36713518 DOI: 10.3389/fonc.2022.1071171] [Reference Citation Analysis]
2 Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol 2023;98:193-209. [PMID: 36226409 DOI: 10.1002/ajh.26760] [Reference Citation Analysis]
3 Hughes MS, Sterling CH, Varadhan R, Ambinder RF, Jones RJ, Sweren RJ, Rozati S, Bolaños-Meade J, Luznik L, Imus PH, Ali SA, Borrello IM, Huff CA, Jain T, Ambinder A, DeZern AE, Gocke CB, Gladstone DE, Swinnen LJ, Wagner-Johnston ND, Fuchs EJ. Mismatched donor transplantation with post-transplantation cyclophosphamide for advanced cutaneous T-cell lymphoma: a single-center retrospective study. Leuk Lymphoma 2022;63:2987-91. [PMID: 35915978 DOI: 10.1080/10428194.2022.2105330] [Reference Citation Analysis]
4 Snowden JA, Sánchez-Ortega I, Corbacioglu S, Basak GW, Chabannon C, de la Camara R, Dolstra H, Duarte RF, Glass B, Greco R, Lankester AC, Mohty M, Neven B, de Latour RP, Pedrazzoli P, Peric Z, Yakoub-Agha I, Sureda A, Kröger N; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2022. Bone Marrow Transplant 2022. [PMID: 35589997 DOI: 10.1038/s41409-022-01691-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
5 Yonekura K. Current treatment strategies and emerging therapies for cutaneous lymphoma. J Dermatol 2021. [PMID: 34958516 DOI: 10.1111/1346-8138.16289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021;96:1313-28. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
7 Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides und Sézary-Syndrom. J Dtsch Dermatol Ges 2021;19:1307-35. [PMID: 34541808 DOI: 10.1111/ddg.14610_g] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Jonak C, Tittes J, Brunner PM, Guenova E. Mycosis fungoides and Sézary syndrome. J Dtsch Dermatol Ges 2021;19:1307-34. [PMID: 34541796 DOI: 10.1111/ddg.14610] [Reference Citation Analysis]
9 Papadavid E, Kapniari E, Pappa V, Nikolaou V, Iliakis T, Dalamaga M, Jonak C, Porkert S, Engelina S, Quaglino P, Ortiz-Romero PL, Vico C, Cozzio A, Dimitriou F, Guiron R, Guenova E, Hodak E, Bagot M, Scarisbrick J. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity. Br J Dermatol 2021. [PMID: 34137025 DOI: 10.1111/bjd.20588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 de Masson A, Peffault de Latour R, Ram-wolff C, Bagot M. Traitement des lymphomes T cutanés par allogreffe de cellules souches hématopoïétiques. Annales de Dermatologie et de Vénéréologie - FMC 2021;1:187-192. [DOI: 10.1016/j.fander.2020.07.004] [Reference Citation Analysis]
11 Domingo-Domenech E, Duarte RF, Boumedil A, Onida F, Gabriel I, Finel H, Arcese W, Browne P, Beelen D, Kobbe G, Veelken H, Arranz R, Greinix H, Lenhoff S, Poiré X, Ribera JM, Thompson J, Zuckerman T, Mufti GJ, Cortelezzi A, Olavarria E, Dreger P, Sureda A, Montoto S. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sézary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 2021;56:1391-401. [PMID: 33420392 DOI: 10.1038/s41409-020-01197-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
12 Salas MQ, Viswabandya A. HSCT in Malignancies. Contemporary Bone Marrow Transplantation 2021. [DOI: 10.1007/978-3-030-36358-1_33] [Reference Citation Analysis]
13 Willemze R, Theurich S, Schlaak M. Indolent Cutaneous T-Cell Lymphomas. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-55989-2_14] [Reference Citation Analysis]
14 Sivanand A, Hennessey D, Iyer A, O'Keefe S, Surmanowicz P, Vaid G, Xiao Z, Gniadecki R. The Neoantigen Landscape of Mycosis Fungoides. Front Immunol 2020;11:561234. [PMID: 33329522 DOI: 10.3389/fimmu.2020.561234] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
15 Bolcato V, Barruscotti S, DE Silvestri A, Tomasini CF, Brazzelli V. Sézary Syndrome: a clinico-pathological study of 9 cases. Ital J Dermatol Venerol 2021;156:73-83. [PMID: 33084262 DOI: 10.23736/S2784-8671.19.06403-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Dumont M, Peffault de Latour R, Ram-Wolff C, Bagot M, de Masson A. Allogeneic Hematopoietic Stem Cell Transplantation in Cutaneous T-Cell Lymphomas. Cancers (Basel) 2020;12:E2856. [PMID: 33023002 DOI: 10.3390/cancers12102856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
17 Sivanand A, Hennessey D, Iyer A, O’keefe S, Surmanowicz P, Vaid G, Gniadecki R. The neoantigen landscape of mycosis fungoides.. [DOI: 10.1101/2020.01.22.915280] [Reference Citation Analysis]
18 Voorhees TJ, Bowers EV, Kelsey CR, Park Y, Beaven AW. Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sézary Syndrome. Novel Therapeutics for Rare Lymphomas 2020. [DOI: 10.1007/978-3-030-25610-4_14] [Reference Citation Analysis]
19 Salas MQ, Viswabandya A. HSCT in Malignancies. Contemporary Bone Marrow Transplantation 2020. [DOI: 10.1007/978-3-319-64938-2_33-1] [Reference Citation Analysis]
20 Martinez XU, Di Raimondo C, Abdulla FR, Zain J, Rosen ST, Querfeld C. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome. Best Pract Res Clin Haematol 2019;32:239-52. [PMID: 31585624 DOI: 10.1016/j.beha.2019.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
21 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 12.3] [Reference Citation Analysis]
22 Specht L, Skov L. Cutaneous Lymphomas. Clin Oncol (R Coll Radiol) 2019;31:797-807. [PMID: 31405542 DOI: 10.1016/j.clon.2019.07.018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
23 Sivanand A, Surmanowicz P, Alhusayen R, Hull P, Litvinov IV, Zhou Y, Gniadecki R. Immunotherapy for Cutaneous T-Cell Lymphoma: Current Landscape and Future Developments. J Cutan Med Surg 2019;23:537-44. [PMID: 31353944 DOI: 10.1177/1203475419867610] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
24 Jonak C. CD8+ mycosis fungoides: a wolf in sheep's clothing? Br J Dermatol 2019;181:1126-7. [PMID: 31241759 DOI: 10.1111/bjd.17881] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
25 Duarte RF, Labopin M, Bader P, Basak GW, Bonini C, Chabannon C, Corbacioglu S, Dreger P, Dufour C, Gennery AR, Kuball J, Lankester AC, Lanza F, Montoto S, Nagler A, Peffault de Latour R, Snowden JA, Styczynski J, Yakoub-Agha I, Kröger N, Mohty M; European Society for Blood and Marrow Transplantation (EBMT). Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant 2019;54:1525-52. [PMID: 30953028 DOI: 10.1038/s41409-019-0516-2] [Cited by in Crossref: 148] [Cited by in F6Publishing: 154] [Article Influence: 37.0] [Reference Citation Analysis]
26 Arslan S, Hosing C. Hematopoietic Stem Cell Transplantation for Rare Hematological Malignancies. Hematopoietic Cell Transplantation for Malignant Conditions 2019. [DOI: 10.1016/b978-0-323-56802-9.00019-5] [Reference Citation Analysis]
27 Zain J. Transplantation. Cancer Treatment and Research 2019. [DOI: 10.1007/978-3-319-99716-2_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
28 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 80] [Cited by in F6Publishing: 84] [Article Influence: 13.3] [Reference Citation Analysis]
29 Stranzenbach R, Theurich S, Schlaak M. [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma]. Hautarzt 2017;68:716-20. [PMID: 28785925 DOI: 10.1007/s00105-017-4023-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
30 Kharfan-Dabaja MA, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C, d'Amore F, Jantunen E, Ishida T, Bazarbachi A, Foss F, Advani R, Fenske TS, Lazarus HM, Friedberg JW, Aljurf M, Sokol L, Tobinai K, Tse E, Burns LJ, Chavez JC, Reddy NM, Suzuki R, Ahmed S, Nademanee A, Mohty M, Gopal AK, Fanale MA, Pro B, Moskowitz AJ, Sureda A, Perales MA, Carpenter PA, Savani BN. Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23:1826-1838. [PMID: 28797780 DOI: 10.1016/j.bbmt.2017.07.027] [Cited by in Crossref: 96] [Cited by in F6Publishing: 101] [Article Influence: 16.0] [Reference Citation Analysis]
31 Atilla E, Atilla PA, Bozdag SC, Yuksel MK, Toprak SK, Topcuoglu P, Akay BN, Sanli H, Gurman G, Ozcan M. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS). Int J Hematol 2017;106:426-30. [DOI: 10.1007/s12185-017-2245-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
32 Hoppe RT, Kim YH, Advani RH. Mycosis Fungoides and Sézary Syndrome. Holland-Frei Cancer Medicine 2017. [DOI: 10.1002/9781119000822.hfcm121] [Reference Citation Analysis]
33 Smith GL. Radiation Therapy in the Management of Cutaneous T-Cell Lymphomas. Radiation Therapy in Hematologic Malignancies 2017. [DOI: 10.1007/978-3-319-42615-0_12] [Reference Citation Analysis]
34 Whittaker S, Hoppe R, Prince HM. How I treat mycosis fungoides and Sézary syndrome. Blood 2016;127:3142-53. [DOI: 10.1182/blood-2015-12-611830] [Cited by in Crossref: 77] [Cited by in F6Publishing: 82] [Article Influence: 11.0] [Reference Citation Analysis]
35 Patir P, Vural F. Treatment of mycosis fungoides, in the era of stem cell transplantation. World J Dermatol 2016; 5(1): 52-56 [DOI: 10.5314/wjd.v5.i1.52] [Reference Citation Analysis]
36 Smith GL, Wilson LD, Dabaja BS. Mycosis Fungoides. Clinical Radiation Oncology 2016. [DOI: 10.1016/b978-0-323-24098-7.00079-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
37 Zain J, Thomas SH. Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell). Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch58] [Reference Citation Analysis]
38 Pullarkat V, Forman SJ. Hematopoietic Cell Transplantation for Rare Hematologic Malignancies. Thomas’ Hematopoietic Cell Transplantation 2016. [DOI: 10.1002/9781118416426.ch67] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 81] [Cited by in F6Publishing: 88] [Article Influence: 11.6] [Reference Citation Analysis]
40 Virmani P, Zain J, Rosen ST, Myskowski PL, Querfeld C. Hematopoietic Stem Cell Transplant for Mycosis Fungoides and Sézary Syndrome. Dermatologic Clinics 2015;33:807-18. [DOI: 10.1016/j.det.2015.05.014] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
41 Hughes CF, Newland K, Mccormack C, Lade S, Prince HM. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers: Mycosis fungoides and Sézary syndrome. Australasian Journal of Dermatology 2016;57:182-91. [DOI: 10.1111/ajd.12349] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
42 Jacobsen ED. Stem cell transplantation for mycosis fungoides/Sézary syndrome. Clinical Guide to Transplantation in Lymphoma 2015. [DOI: 10.1002/9781118863282.ch23] [Reference Citation Analysis]
43 Chmielowska E, Studziński M, Giebel S, Krause A, Olejniczak M, Grzanka A. Follow-up of patients with mycosis fungoides after interferon α2b treatment failure. Postepy Dermatol Alergol 2015;32:67-72. [PMID: 26015774 DOI: 10.5114/pdia.2014.40941] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
44 Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, Falkenburg JH, Farge-Bancel D, Gennery A, Kröger N, Lanza F, Marsh JC, Nagler A, Peters C, Velardi A, Mohty M, Madrigal A. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transplant 2015;50:1037-56. [PMID: 25798672 DOI: 10.1038/bmt.2015.6] [Cited by in Crossref: 218] [Cited by in F6Publishing: 237] [Article Influence: 27.3] [Reference Citation Analysis]
45 Pawar R, Kasi Loknath Kumar A, Woodroof J, Cui W, McGuirk J, Abhyankar S, Ganguly S, Singh A, Lin T, Aljitawi O. Skin Recurrence of Transformed Mycosis Fungoides Postumbilical Cord Blood Transplant despite Complete Donor Chimerism. Case Rep Hematol 2014;2014:743856. [PMID: 25580315 DOI: 10.1155/2014/743856] [Reference Citation Analysis]
46 Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood 2015;125:71-81. [DOI: 10.1182/blood-2014-07-588236] [Cited by in Crossref: 137] [Cited by in F6Publishing: 139] [Article Influence: 17.1] [Reference Citation Analysis]
47 Wilcox RA. Cutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol 2014;89:837-51. [PMID: 25042790 DOI: 10.1002/ajh.23756] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
48 Lechowicz MJ, Lazarus HM, Carreras J, Laport GG, Cutler CS, Wiernik PH, Hale GA, Maharaj D, Gale RP, Rowlings PA. Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndrome. Bone Marrow Transplant. 2014;49:1360-1365. [PMID: 25068422 DOI: 10.1038/bmt.2014.161] [Cited by in Crossref: 66] [Cited by in F6Publishing: 70] [Article Influence: 7.3] [Reference Citation Analysis]
49 Ram-wolff C. Linfomas T cutáneos de tipo micosis fungoide/síndrome de Sézary (incluida parapsoriasis). EMC - Dermatología 2014;48:1-12. [DOI: 10.1016/s1761-2896(14)67581-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
50 Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions. J Am Acad Dermatol. 2014;70:223.e1-217.e1; quiz 240-242. [PMID: 24438970 DOI: 10.1016/j.jaad.2013.08.033] [Cited by in Crossref: 188] [Cited by in F6Publishing: 206] [Article Influence: 20.9] [Reference Citation Analysis]
51 Kempf W, Kazakov DV, Kerl K. Cutaneous Lymphomas: An Update. Part 1 T-Cell and Natural Killer/T-Cell Lymphomas and Related Conditions. The American Journal of Dermatopathology 2014;36:105-23. [DOI: 10.1097/dad.0b013e318289b1db] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]
52 Guenova E, Hoetzenecker W, Rozati S, Levesque MP, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold? Expert Opin Investig Drugs 2014;23:457-67. [PMID: 24397291 DOI: 10.1517/13543784.2014.876407] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
53 Zain J, Weichenthal M, Rodig S, Delabie J. Cutaneous T-Cell Lymphoma. Rare Lymphomas 2014. [DOI: 10.1007/978-3-642-39590-1_8] [Reference Citation Analysis]
54 de Masson A, Beylot-Barry M, Bouaziz JD, Peffault de Latour R, Aubin F, Garciaz S, d’Incan M, Dereure O, Dalle S, Dompmartin A. Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. Haematologica. 2014;99:527-534. [PMID: 24213148 DOI: 10.3324/haematol.2013.098145] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 5.9] [Reference Citation Analysis]
55 Dummer R, Rozati S, Guenova E, Cozzio A. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. Future Oncol 2013;9:1061-4. [PMID: 23902236 DOI: 10.2217/fon.13.87] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
56 Willemze R, Hodak E, Zinzani P, Specht L, Ladetto M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2013;24:vi149-54. [DOI: 10.1093/annonc/mdt242] [Cited by in Crossref: 99] [Cited by in F6Publishing: 107] [Article Influence: 9.9] [Reference Citation Analysis]
57 Moraes FY, Carvalho Hde A, Hanna SA, Silva JL, Marta GN. Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults. Rep Pract Oncol Radiother 2014;19:92-8. [PMID: 24936326 DOI: 10.1016/j.rpor.2013.08.003] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
58 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev 2013;:CD008908. [PMID: 23986525 DOI: 10.1002/14651858.CD008908.pub3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
59 Duvic M. Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome. Lymphoma 2013. [DOI: 10.1007/978-1-62703-408-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
60 Songdej N, Winer ES. Autologous Hematopoietic Stem Cell Transplantation in Non-Hodgkin Lymphomas. Non-Hodgkin Lymphoma 2013. [DOI: 10.1007/978-1-4614-5851-7_14] [Reference Citation Analysis]
61 Rodríguez J, Corradini P. Autologous and Allogeneic Stem Cell Transplantation for T-Cell Lymphomas. T-Cell Lymphomas 2013. [DOI: 10.1007/978-1-62703-170-7_13] [Reference Citation Analysis]
62 Schlaak M, Theurich S, Pickenhain J, Skoetz N, Kurschat P, von Bergwelt-baildon M. Allogeneic stem cell transplantation for advanced primary cutaneous T-cell lymphoma: A systematic review. Critical Reviews in Oncology/Hematology 2013;85:21-31. [DOI: 10.1016/j.critrevonc.2012.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.8] [Reference Citation Analysis]
63 Izu-belloso R, García-ruiz J. Actualización terapéutica en linfomas cutáneos. Actas Dermo-Sifiliográficas 2012;103:694-707. [DOI: 10.1016/j.ad.2012.01.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
64 Izu-belloso R, García-ruiz J. Treatment of Cutaneous Lymphomas: an Update. Actas Dermo-Sifiliográficas (English Edition) 2012;103:694-707. [DOI: 10.1016/j.adengl.2012.09.016] [Reference Citation Analysis]
65 Bloom T, Kuzel TM, Querfeld C, Guitart J, Rosen ST. Cutaneous T-cell lymphomas: a review of new discoveries and treatments. Curr Treat Options Oncol 2012;13:102-21. [PMID: 22311555 DOI: 10.1007/s11864-011-0179-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
66 Schlaak M, Pickenhain J, Theurich S, Skoetz N, von Bergwelt-Baildon M, Kurschat P. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database Syst Rev. 2012;1:CD008908. [PMID: 22258991 DOI: 10.1002/14651858.cd008908.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
67 Tse E, Kwong YL. Treatment algorithms for mature T-cell and natural killer-cell neoplasms. Future Oncol 2011;7:1101-12. [PMID: 21919697 DOI: 10.2217/fon.11.84] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
68 Gulia A, Massone C. Primary cutaneous T-cell lymphomas. Journal of the Egyptian Womenʼs Dermatologic Society 2012;9:1-13. [DOI: 10.1097/01.ewx.0000407896.95730.63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [PMID: 21990092 DOI: 10.1002/ajh.22139] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
70 Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol 2011;155:150-66. [PMID: 21883142 DOI: 10.1111/j.1365-2141.2011.08852.x] [Cited by in Crossref: 105] [Cited by in F6Publishing: 109] [Article Influence: 8.8] [Reference Citation Analysis]
71 Koch R, Jaffe ES, Mensing C, Zeis M, Schmitz N, Sander CA. Cutaneous gamma/delta T-cell lymphoma. J Dtsch Dermatol Ges 2009;7:1065-7. [PMID: 19694889 DOI: 10.1111/j.1610-0387.2009.07209.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
72 Kikuchi Y, Kashii Y, Gunji Y, Morimoto A, Masuzawa A, Takatsuka Y, Fujita E, Komine M, Ohtsuki M, Matsubara D, Kobayashi C, Sakurai A, Yanase K, Kato K, Koike K, Tsuchida M, Momoi MY. Six-year-old girl with primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: PTCL-unspecified. Pediatrics International 2011;53:393-6. [DOI: 10.1111/j.1442-200x.2011.03369.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
73 Klemke C. Systemische Therapie kutaner Lymphome. Hautarzt 2011;62:436-43. [DOI: 10.1007/s00105-010-2043-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
74 Delioukina M, Zain J, Palmer JM, Tsai N, Thomas S, Forman S. Reduced-intensity allogeneic hematopoietic cell transplantation using fludarabine-melphalan conditioning for treatment of mature T-cell lymphomas. Bone Marrow Transplant 2012;47:65-72. [PMID: 21358679 DOI: 10.1038/bmt.2011.16] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
75 Olsen EA, Rook AH, Zic J, Kim Y, Porcu P, Querfeld C, Wood G, Demierre M, Pittelkow M, Wilson LD, Pinter-brown L, Advani R, Parker S, Kim EJ, Junkins-hopkins JM, Foss F, Cacchio P, Duvic M. Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). Journal of the American Academy of Dermatology 2011;64:352-404. [DOI: 10.1016/j.jaad.2010.08.037] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 10.3] [Reference Citation Analysis]
76 Schlaak M, Theurich S, Skoetz N, Pickenhain J, Engert A, Kurschat P, Bergwelt-baildon M. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T cell lymphoma. Cochrane Database of Systematic Reviews 2010. [DOI: 10.1002/14651858.cd008908] [Reference Citation Analysis]
77 Beylot-barry M, Dereure O, Vergier B, Barete S, Laroche L, Machet L, Delfau-larue M, D’incan M, Grange F, Ortonne N, Merlio J, Bagot M. Prise en charge des lymphomes T cutanés : recommandations du Groupe français d’étude des lymphomes cutanés. Annales de Dermatologie et de Vénéréologie 2010;137:611-21. [DOI: 10.1016/j.annder.2010.06.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
78 Devine SM. Hematopoietic stem cell transplantation for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma Leuk 2010;10 Suppl 2:S96-8. [PMID: 20826408 DOI: 10.3816/CLML.2010.s.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
79 Poligone B, Heald P. Innovative therapy of cutaneous T-cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatol Clin 2010;28:501-10. [PMID: 20510760 DOI: 10.1016/j.det.2010.03.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
80 Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, Ferrant A, Kobbe G, Narni F, Deliliers GL. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:4492-4499. [PMID: 20697072 DOI: 10.1200/jco.2010.29.3241] [Cited by in Crossref: 144] [Cited by in F6Publishing: 157] [Article Influence: 11.1] [Reference Citation Analysis]
81 Whittaker SJ. Cutaneous Lymphomas and Lymphocytic Infiltrates. Rook's Textbook of Dermatology 2010. [DOI: 10.1002/9781444317633.ch57] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
82 Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2010;21:v177-80. [DOI: 10.1093/annonc/mdq183] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
83 Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, Acholonu S, Khouri I, Champlin R, Hosing C. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. J Clin Oncol. 2010;28:2365-2372. [PMID: 20351328 DOI: 10.1200/jco.2009.25.8301] [Cited by in Crossref: 118] [Cited by in F6Publishing: 124] [Article Influence: 9.1] [Reference Citation Analysis]
84 Hoppe RT, Advani R, Kim YH. Mycosis Fungoides. Leibel and Phillips Textbook of Radiation Oncology 2010. [DOI: 10.1016/b978-1-4160-5897-7.00064-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Kirby JS, Kim EJ, Rook AH. Therapy of Sézary syndrome. Expert Review of Dermatology 2009;4:567-579. [DOI: 10.1586/edm.09.57] [Reference Citation Analysis]
86 Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood 2009;114:4337-53. [DOI: 10.1182/blood-2009-07-202895] [Cited by in Crossref: 108] [Cited by in F6Publishing: 115] [Article Influence: 7.7] [Reference Citation Analysis]
87 Mestel D, Beyer M, Steinhoff M, Sterry W. Treatment of Cutaneous Lymphomas: Today and Tomorrow. Actas Dermo-Sifiliográficas 2009;100:18-32. [DOI: 10.1016/s0001-7310(09)73165-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
88 Gallipoli P, Clark A, Leach M. The evolving management of a rare lymphoproliferative disorder-T-cell prolymphocytic leukemia. Am J Hematol 2009;84:750-3. [PMID: 19714590 DOI: 10.1002/ajh.21498] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
89 Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl-Goldstein KE. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biol Blood Marrow Transplant 2009;15:982-90. [PMID: 19589488 DOI: 10.1016/j.bbmt.2009.04.017] [Cited by in Crossref: 89] [Cited by in F6Publishing: 90] [Article Influence: 6.4] [Reference Citation Analysis]
90 Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T-cell lymphoma. Current Opinion in Oncology 2009;21:131-7. [DOI: 10.1097/cco.0b013e3283253190] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
91 John Wiley & Sons, Ltd. Current Awareness in Hematological Oncology. Hematol Oncol 2008;26:253-60. [DOI: 10.1002/hon.833] [Reference Citation Analysis]
92 Cudillo L, Cerretti R, Baliva G, De Angelis G, Postorino M, Picardi A, Mirabile M, Lanti A, Cantonetti M, Arcese W; for the Rome Transplant Network. Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. Bone Marrow Transplant 2009;43:347-8. [DOI: 10.1038/bmt.2008.333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]